See more : Quantum-Si incorporated (QSIAW) Income Statement Analysis – Financial Results
Complete financial analysis of Teleflex Incorporated (TFX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Teleflex Incorporated, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- China Apex Group Limited (2011.HK) Income Statement Analysis – Financial Results
- S&T Bancorp, Inc. (STBA) Income Statement Analysis – Financial Results
- Kino Polska TV Spolka Akcyjna (KPL.WA) Income Statement Analysis – Financial Results
- Patrys Limited (PAB.AX) Income Statement Analysis – Financial Results
- Frigoglass S.A.I.C. (FRIGO.AT) Income Statement Analysis – Financial Results
Teleflex Incorporated (TFX)
About Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.97B | 2.79B | 2.81B | 2.54B | 2.60B | 2.45B | 2.15B | 1.87B | 1.81B | 1.84B | 1.70B | 1.55B | 1.53B | 1.80B | 1.89B | 2.42B | 1.93B | 2.65B | 2.51B | 2.49B | 2.28B | 2.08B | 1.91B | 1.76B | 1.60B | 1.44B | 1.15B | 931.20M | 912.70M | 812.70M | 666.80M | 567.10M | 479.50M | 441.10M | 355.60M | 328.20M | 269.80M | 214.20M | 171.80M |
| Cost of Revenue | 1.33B | 1.26B | 1.26B | 1.21B | 1.10B | 1.06B | 974.50M | 871.83M | 865.29M | 897.40M | 857.33M | 802.78M | 810.07M | 1.01B | 1.08B | 1.46B | 1.25B | 1.87B | 1.80B | 1.79B | 1.68B | 1.52B | 1.37B | 1.20B | 1.09B | 969.60M | 746.90M | 601.40M | 590.30M | 524.40M | 431.00M | 360.40M | 311.80M | 286.90M | 237.20M | 215.50M | 175.80M | 140.50M | 114.70M |
| Gross Profit | 1.65B | 1.53B | 1.55B | 1.32B | 1.49B | 1.38B | 1.17B | 996.20M | 944.40M | 942.43M | 838.95M | 748.23M | 718.84M | 794.07M | 814.08M | 964.17M | 680.35M | 774.19M | 709.95M | 698.80M | 597.79M | 552.45M | 535.29M | 567.70M | 512.60M | 468.00M | 398.90M | 329.80M | 322.40M | 288.30M | 235.80M | 206.70M | 167.70M | 154.20M | 118.40M | 112.70M | 94.00M | 73.70M | 57.10M |
| Gross Profit Ratio | 55.37% | 54.86% | 55.15% | 52.22% | 57.47% | 56.55% | 54.60% | 53.33% | 52.19% | 51.22% | 49.46% | 48.24% | 47.02% | 44.07% | 43.07% | 39.83% | 35.17% | 29.25% | 28.23% | 28.12% | 26.19% | 26.61% | 28.10% | 32.17% | 32.02% | 32.55% | 34.81% | 35.42% | 35.32% | 35.47% | 35.36% | 36.45% | 34.97% | 34.96% | 33.30% | 34.34% | 34.84% | 34.41% | 33.24% |
| Research & Development | 154.35M | 153.82M | 130.84M | 119.75M | 113.86M | 106.21M | 84.77M | 58.58M | 52.12M | 61.04M | 65.05M | 56.28M | 48.73M | 42.62M | 0.00 | 0.00 | 30.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 991.05M | 863.75M | 860.09M | 743.57M | 934.37M | 878.69M | 699.96M | 563.31M | 568.98M | 578.66M | 502.19M | 454.49M | 429.26M | 475.32M | 519.93M | 596.77M | 445.25M | 493.52M | 449.04M | 494.43M | 423.03M | 365.02M | 347.13M | 311.28M | 284.70M | 266.10M | 230.20M | 190.30M | 192.40M | 173.90M | 141.00M | 124.20M | 93.70M | 84.80M | 63.90M | 59.10M | 49.60M | 39.80M | 31.70M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 582.00K | -341.00K | 2.60M | 2.34M | 0.00 | 838.00K | -14.22M | -2.73M | -1.93B | -18.90M | 0.00 | 77.42M | 67.40M | 60.10M | 47.90M | 38.80M | 37.70M | 33.00M | 28.10M | 21.60M | 18.40M | 17.20M | 12.90M | 11.00M | 9.80M | 7.20M | 4.80M |
| Operating Expenses | 1.14B | 1.02B | 990.93M | 863.32M | 1.05B | 984.90M | 784.73M | 621.89M | 621.10M | 639.70M | 567.23M | 510.77M | 478.58M | 517.60M | 522.52M | 624.18M | 445.25M | 494.35M | 434.82M | 491.70M | -1.51B | 346.12M | 347.13M | 388.70M | 352.10M | 326.20M | 278.10M | 229.10M | 230.10M | 206.90M | 169.10M | 145.80M | 112.10M | 102.00M | 76.80M | 70.10M | 59.40M | 47.00M | 36.50M |
| Cost & Expenses | 2.47B | 2.28B | 2.25B | 2.08B | 2.15B | 2.05B | 1.76B | 1.49B | 1.49B | 1.54B | 1.42B | 1.31B | 1.29B | 1.53B | 1.60B | 2.08B | 1.70B | 2.37B | 2.24B | 2.28B | 177.83M | 1.87B | 1.72B | 1.59B | 1.44B | 1.30B | 1.03B | 830.50M | 820.40M | 731.30M | 600.10M | 506.20M | 423.90M | 388.90M | 314.00M | 285.60M | 235.20M | 187.50M | 151.20M |
| Interest Income | 12.78M | 912.00K | 1.33M | 1.16M | 1.74M | 944.00K | 771.00K | 474.00K | 532.00K | 706.00K | 624.00K | 1.57M | 1.26M | 861.00K | 2.54M | 2.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 85.08M | 54.26M | 56.97M | 66.49M | 80.27M | 103.02M | 82.55M | 54.94M | 61.32M | 65.46M | 56.91M | 69.57M | 70.32M | 80.03M | 89.46M | 121.65M | 0.00 | 0.00 | 0.00 | 37.12M | 26.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 242.12M | 230.59M | 237.36M | 227.25M | 214.06M | 209.98M | 155.26M | 117.91M | 108.39M | 111.13M | 92.98M | 80.47M | 85.62M | 92.19M | 101.06M | 111.22M | 78.76M | 99.00M | 100.85M | 114.60M | 104.35M | 95.12M | 92.40M | 77.42M | 67.40M | 60.10M | 47.90M | 38.80M | 37.70M | 33.00M | 28.10M | 21.60M | 18.40M | 17.20M | 12.90M | 11.00M | 9.80M | 7.20M | 4.80M |
| EBITDA | 761.21M | 751.65M | 873.10M | 665.98M | 634.24M | 532.63M | 522.72M | 418.57M | 414.36M | 396.70M | 325.61M | -26.39M | 288.87M | 302.71M | 353.78M | 453.84M | 313.86M | 309.20M | 284.14M | 308.41M | 302.80M | 307.27M | 280.56M | 256.42M | 227.90M | 201.90M | 168.70M | 139.50M | 130.00M | 114.40M | 94.80M | 82.50M | 74.00M | 69.40M | 54.50M | 53.60M | 44.40M | 33.90M | 25.40M |
| EBITDA Ratio | 25.59% | 26.69% | 28.38% | 27.19% | 25.40% | 24.93% | 25.30% | 26.38% | 23.88% | 22.53% | 21.54% | 20.60% | 15.80% | 20.51% | 20.91% | 18.75% | 19.40% | 15.30% | 15.46% | 15.55% | 96.65% | 14.03% | 14.73% | 14.53% | 14.23% | 14.04% | 14.72% | 14.98% | 14.24% | 14.08% | 14.22% | 13.98% | 14.70% | 15.03% | 14.09% | 16.33% | 15.72% | 13.96% | 12.92% |
| Operating Income | 506.31M | 499.73M | 628.10M | 423.07M | 427.25M | 321.70M | 372.28M | 319.45M | 315.89M | 284.86M | 233.26M | -97.38M | 233.17M | 273.59M | 269.77M | 339.99M | 192.64M | 254.61M | 248.07M | 139.49M | 2.10B | 206.33M | 188.16M | 179.00M | 160.50M | 141.80M | 120.80M | 100.70M | 92.30M | 81.40M | 66.70M | 60.90M | 55.60M | 52.20M | 41.60M | 42.60M | 34.60M | 26.70M | 20.60M |
| Operating Income Ratio | 17.02% | 17.90% | 22.36% | 16.67% | 16.46% | 13.14% | 17.35% | 17.10% | 17.46% | 15.48% | 13.75% | -6.28% | 15.25% | 15.19% | 14.27% | 14.04% | 9.96% | 9.62% | 9.87% | 5.61% | 92.21% | 9.94% | 9.88% | 10.14% | 10.02% | 9.86% | 10.54% | 10.81% | 10.11% | 10.02% | 10.00% | 10.74% | 11.60% | 11.83% | 11.70% | 12.98% | 12.82% | 12.46% | 11.99% |
| Total Other Income/Expenses | -72.30M | -53.81M | -68.63M | -65.34M | -122.08M | 23.20M | -87.37M | -73.73M | -71.25M | -64.75M | -57.53M | -181.78M | -84.47M | -82.50M | -86.92M | -119.01M | -83.29M | -35.93M | -39.67M | -42.35M | -23.27M | -33.84M | -28.47M | -20.79M | -17.77M | -16.98M | -14.40M | -13.90M | -18.70M | -18.40M | -14.40M | -12.30M | -10.30M | -9.30M | -2.40M | -6.20M | -2.90M | 200.00K | 1.60M |
| Income Before Tax | 434.01M | 445.92M | 559.47M | 357.73M | 339.90M | 219.63M | 284.91M | 245.73M | 244.65M | 220.11M | 175.73M | -165.37M | 148.70M | 147.79M | 182.85M | 220.98M | 109.35M | 219.03M | 207.92M | 102.37M | 151.49M | 172.49M | 159.70M | 158.21M | 142.70M | 124.80M | 106.40M | 86.80M | 73.60M | 63.00M | 52.30M | 48.60M | 45.30M | 42.90M | 39.20M | 36.40M | 31.70M | 26.90M | 22.20M |
| Income Before Tax Ratio | 14.59% | 15.98% | 19.91% | 14.10% | 13.10% | 8.97% | 13.27% | 13.15% | 13.52% | 11.96% | 10.36% | -10.66% | 9.73% | 8.20% | 9.67% | 9.13% | 5.65% | 8.28% | 8.27% | 4.12% | 6.64% | 8.31% | 8.38% | 8.97% | 8.91% | 8.68% | 9.29% | 9.32% | 8.06% | 7.75% | 7.84% | 8.57% | 9.45% | 9.73% | 11.02% | 11.09% | 11.75% | 12.56% | 12.92% |
| Income Tax Expense | 76.44M | 83.00M | 74.35M | 21.93M | -122.08M | 23.20M | 129.65M | 8.07M | 7.84M | 28.65M | 23.55M | 16.41M | 27.00M | 21.89M | 39.90M | 52.17M | 122.77M | 54.14M | 47.81M | 14.35M | 42.39M | 47.22M | 47.38M | 48.99M | 47.50M | 42.20M | 36.30M | 29.60M | 24.70M | 21.80M | 18.60M | 16.60M | 15.50M | 14.30M | 12.40M | 12.40M | 12.00M | 10.50M | 8.90M |
| Net Income | 356.33M | 363.14M | 485.37M | 335.32M | 461.47M | 200.80M | 152.53M | 237.38M | 244.86M | 187.68M | 150.88M | -190.06M | 323.33M | 201.09M | 302.99M | 119.77M | 146.48M | 139.43M | 138.82M | 9.52M | 109.10M | 125.27M | 112.31M | 109.22M | 95.20M | 82.60M | 70.10M | 57.20M | 48.90M | 41.20M | 33.70M | 32.90M | 29.80M | 28.60M | 26.80M | 24.00M | 19.70M | 16.40M | 13.30M |
| Net Income Ratio | 11.98% | 13.01% | 17.28% | 13.22% | 17.78% | 8.20% | 7.11% | 12.71% | 13.53% | 10.20% | 8.89% | -12.25% | 21.15% | 11.16% | 16.03% | 4.95% | 7.57% | 5.27% | 5.52% | 0.38% | 4.78% | 6.03% | 5.90% | 6.19% | 5.95% | 5.75% | 6.12% | 6.14% | 5.36% | 5.07% | 5.05% | 5.80% | 6.21% | 6.48% | 7.54% | 7.31% | 7.30% | 7.66% | 7.74% |
| EPS | 7.58 | 7.74 | 10.38 | 7.21 | 9.99 | 4.39 | 3.39 | 5.48 | 5.89 | 4.54 | 3.67 | -4.65 | 7.98 | 5.04 | 7.63 | 3.03 | 3.73 | 3.51 | 3.43 | 0.24 | 2.76 | 3.12 | 2.90 | 2.86 | 2.52 | 2.21 | 1.91 | 1.58 | 1.38 | 1.18 | 0.98 | 0.97 | 0.89 | 0.87 | 0.82 | 0.74 | 0.60 | 0.51 | 0.42 |
| EPS Diluted | 7.53 | 7.68 | 10.23 | 7.09 | 9.80 | 4.29 | 3.27 | 4.98 | 5.10 | 4.04 | 3.45 | -4.65 | 7.92 | 4.99 | 7.59 | 3.01 | 3.73 | 3.49 | 3.39 | 0.24 | 2.73 | 3.08 | 2.86 | 2.83 | 2.47 | 2.15 | 1.86 | 1.58 | 1.38 | 1.18 | 0.98 | 0.97 | 0.89 | 0.87 | 0.82 | 0.74 | 0.60 | 0.51 | 0.42 |
| Weighted Avg Shares Out | 46.98M | 46.90M | 46.77M | 46.49M | 46.20M | 45.69M | 45.00M | 43.33M | 41.56M | 41.37M | 41.11M | 40.86M | 40.50M | 39.91M | 39.72M | 39.58M | 39.26M | 39.76M | 40.52M | 40.21M | 39.60M | 40.15M | 38.73M | 38.19M | 37.78M | 37.38M | 36.70M | 36.20M | 35.56M | 35.06M | 34.39M | 33.92M | 33.48M | 32.87M | 32.68M | 32.43M | 32.83M | 32.16M | 31.67M |
| Weighted Avg Shares Out (Dil) | 47.30M | 47.31M | 47.43M | 47.29M | 47.09M | 46.80M | 46.66M | 47.65M | 48.06M | 46.47M | 43.69M | 40.86M | 40.80M | 40.28M | 39.94M | 39.83M | 39.26M | 39.99M | 40.96M | 40.50M | 39.94M | 40.67M | 39.27M | 38.60M | 38.54M | 38.42M | 37.69M | 36.20M | 35.56M | 35.06M | 34.39M | 33.92M | 33.48M | 32.87M | 32.68M | 32.43M | 32.83M | 32.16M | 31.67M |
Here's Why You Should Retain Teleflex (TFX) Stock for Now
Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.
Teleflex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WAYNE, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 42nd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco, California, on...
Glancy Prongay & Murray LLP Announces Investigation of Teleflex Incorporated (TFX)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSE: TFX) concerning the Company and its directors' and officers' possible violations of state laws. If you own Teleflex stock, would like to learn more about...
Teleflex (TFX) Signs Peripheral Access Purchasing Deal With PINC
Teleflex (TFX) secures the Peripheral Access purchasing agreement with Premier, Inc.
Teleflex Awarded Peripheral Access Agreement with Premier, Inc.
WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc. Effective December 1st, 2023, the new agreement allows...
Should You Pick Teleflex Stock After 20% Gains This Month?
Teleflex stock (NYSE: TFX), which provides instruments and consumables for laboratories, trades at $220 per share, 50% below the level seen in March 2021.
December Looks Great For Investors Who Own 9 Stocks
Investors can only hope stocks do as well in December as they did in November. There are definitely some S&P 500 stocks that glisten.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
Investors remain optimistic about Teleflex (TFX) on the strength of the Vascular and Interventional businesses.
Teleflex (TFX) Enrolls First Patient in ACCESS-MANTA Registry
Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.
Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry
Registry Intends to Examine Contemporary On-Label Use of the MANTA™ Vascular Closure Device Including Appropriate Patient Selection and Proper Vascular Access Registry Intends to Examine Contemporary On-Label Use of the MANTA™ Vascular Closure Device Including Appropriate Patient Selection and Proper...
Source: https://incomestatements.info
Category: Stock Reports